PRLD
USDPrelude Therapeutics Incorporated Common Stock
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$1.190
고가
$1.280
저가
$1.173
거래량
1.13M
기업 기본 정보
시가총액
71.5M
산업
생명공학
국가
United States
거래 통계
평균 거래량
1.27M
거래소
NMS
통화
USD
52주 범위
관련 뉴스
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with
Prelude Therapeutics Announces Strategic Business Update
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of two
